Long-Term Survival and Predictive Relevance of Nocturnal Ventricular Tachyarrhythmias Requiring Appropriate Implantable Cardioverter-Defibrillator Therapy
- 1Department of Cardiology, Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, 100020 Beijing, China
- 2Arrhythmia Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China
Abstract
Background:: Whether nocturnal ventricular tachyarrhythmias (VTAs) are associated with poorer long-term survival than daytime VTAs remains unclear. This study aimed to investigate the association between nocturnal VTAs and long-term survival, as well as the associated prognostic relevance.
Methods:: Implantable cardioverter-defibrillator (ICD) recipients from the Study of Home Monitoring System Safety and Efficacy in Cardiac Implantable Electronic Device-implanted Patients (SUMMIT) registry were retrospectively analyzed using data from home monitoring transmissions. Nocturnal VTAs were defined as episodes occurring between 22:00 and 05:59, whereas daytime VTAs were defined as those occurring during the remaining 16 hours (06:00–21:59).
Results:: Over a median follow-up of 61.7 months, 102 cardiac deaths and 187 deaths from any cause were recorded. Among 730 patients, 422 experienced VTAs, of whom 231 (54.7%) had nocturnal VTAs. Compared with patients without VTAs, those with nocturnal VTAs had a 62% higher risk of cardiac death (hazard ratio (HR), 1.62; 95% confidence interval (CI): 1.02–2.59; p = 0.041) and a 2.3-fold higher risk of all-cause mortality (HR, 2.30; 95% CI: 1.50–3.53; p < 0.001). Patients with nocturnal VTAs experienced more ICD shocks (77.9% [180/231] vs. 59.2% [113/191]; p < 0.001), more electrical storms (46.8% [108/231] vs. 9.4% [18/191]; p < 0.001), and a higher VTA burden (median, 1.36 [IQR, 3.44] vs. 0.59 [IQR, 1.01] episodes per year) than those with daytime-only VTAs. Elevated nighttime heart rate and reduced left ventricular ejection fraction (LVEF), as well as male sex and prior atrial fibrillation, were identified as independent risk factors for nocturnal VTAs.
Conclusions:: Nocturnal VTAs were not uncommon. Patients experiencing nocturnal VTAs had a higher risk of cardiac death and all-cause mortality. Monitoring the occurrence and timing of VTA episodes may be a useful tool for identifying high-risk patients.
Clinical Trial Registration:: ChiCTR-ONRC-13003695, https://www.chictr.org.cn/showproj.html?proj=5865.
Related
- Radiofrequency ablation with a conventional solid tip catheter in contact with an implantable cardioverter-defibrillator coil causing inadvertent ventricular fibrillation.
- Ventricular fibrillation treated by an implantable cardioverter-defibrillator in antimitochondrial M2 antibody-positive myocarditis.
- Transient defibrillation threshold elevation associated with air in the generator pocket after extravascular implantable cardioverter-defibrillator implantation.
- Intraoperative preservation of an extravascular implantable cardioverter-defibrillator lead during coronary artery bypass grafting.
- Electrode perforation of a silicone breast implant in a subcutaneous implantable cardioverter-defibrillator carrier: A previously unreported device complication.
BibTeX
@article{sun2026longterm,
title = {{Long-Term Survival and Predictive Relevance of Nocturnal Ventricular Tachyarrhythmias Requiring Appropriate Implantable Cardioverter-Defibrillator Therapy}},
author = {Xuerong Sun and Xiaofeng Li and Shuang Zhao and Shu Zhang and Xingpeng Liu},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.31083/rcm51312},
url = {https://doi.org/10.31083/rcm51312},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Long-Term Survival and Predictive Relevance of Nocturnal Ventricular Tachyarrhythmias Requiring Appropriate Implantable Cardioverter-Defibrillator Therapy
AU - Xuerong Sun
AU - Xiaofeng Li
AU - Shuang Zhao
AU - Shu Zhang
AU - Xingpeng Liu
PY - 2026
DA - 2026/10/16
JO - Reviews in Cardiovascular Medicine
DO - 10.31083/rcm51312
UR - https://doi.org/10.31083/rcm51312
AB - Background:: Whether nocturnal ventricular tachyarrhythmias (VTAs) are associated with poorer long-term survival than daytime VTAs remains unclear. This study aimed to investigate the association between nocturnal VTAs and long-term survival, as well as the associated prognostic relevance. Methods:: Implantable cardioverter-defibrillator (ICD) recipients from the Study of Home Monitoring System Safety and Efficacy in Cardiac Implantable Electronic Device-implanted Patients (SUMMIT) registry were retrospectively analyzed using data from home monitoring transmissions. Nocturnal VTAs were defined as episodes occurring between 22:00 and 05:59, whereas daytime VTAs were defined as those occurring during the remaining 16 hours (06:00–21:59). Results:: Over a median follow-up of 61.7 months, 102 cardiac deaths and 187 deaths from any cause were recorded. Among 730 patients, 422 experienced VTAs, of whom 231 (54.7%) had nocturnal VTAs. Compared with patients without VTAs, those with nocturnal VTAs had a 62% higher risk of cardiac death (hazard ratio (HR), 1.62; 95% confidence interval (CI): 1.02–2.59; p = 0.041) and a 2.3-fold higher risk of all-cause mortality (HR, 2.30; 95% CI: 1.50–3.53; p < 0.001). Patients with nocturnal VTAs experienced more ICD shocks (77.9% [180/231] vs. 59.2% [113/191]; p < 0.001), more electrical storms (46.8% [108/231] vs. 9.4% [18/191]; p < 0.001), and a higher VTA burden (median, 1.36 [IQR, 3.44] vs. 0.59 [IQR, 1.01] episodes per year) than those with daytime-only VTAs. Elevated nighttime heart rate and reduced left ventricular ejection fraction (LVEF), as well as male sex and prior atrial fibrillation, were identified as independent risk factors for nocturnal VTAs. Conclusions:: Nocturnal VTAs were not uncommon. Patients experiencing nocturnal VTAs had a higher risk of cardiac death and all-cause mortality. Monitoring the occurrence and timing of VTA episodes may be a useful tool for identifying high-risk patients. Clinical Trial Registration:: ChiCTR-ONRC-13003695, https://www.chictr.org.cn/showproj.html?proj=5865.
SN - 1530-6550
SN - 2153-8174
ER -